Skip to main content

Anti-Rheumatic Rx

Diet as a DMARD? The Evidence Is Still Hard to Swallow

Dietary interventions are rarely taken as seriously as pharmacological therapies in rheumatology. Yet patients ask about them constantly, and an increasing number of studies suggest that nutrition may influence disease outcomes. Two randomized controlled trials presented at EULAR 2026 add to

Read Article
ULT de-escalation in Gout: shall we do it? Short answer: No RCT 309 pts 24 mo Primary outcome remission last 6 mo 79.2% ULT continuation vs 62.9% discontinuation p=0.002 Flare incidence 12% vs 32% More NSAID/colchicine use after stopping ULT Stopping ULT = urate rises quickly & https://t.co/bYKr5axu46
Aurelie Najm @AurelieRheumo( View Tweet )
#Autoimmune #progressive #pulmonary #fibrosis Large Spanish registry ❎more mortality if not on #DMARDs ?underRx of proven #Rx with #antifibrotics Median survival post #dx #PPF 7.8 yrs Can we do better? #ABST POS0430 @RheumNow #EULAR2026 https://t.co/gP7apxfEPS
Janet Pope @Janetbirdope( View Tweet )
Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
Jiha Lee @JihaRheum( View Tweet )
💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use. As a rheumatologist, do you vaccinate your patients? #EULAR2026 @RheumNow
#Vaccination in Rheum 📍Hold MTX 1-2wks post vax 📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals. THM: Assess vax need at dx, vax w/o delay #EULAR2026 @RheumNow https://t.co/6ptl8gyBLR
Advanced Practice Rheum: Safety of Biologics and Novel Agents Dr. Jack Cush reviews safety of biologics and novel agents. This video is part of the Advanced Practice Rheum series. https://t.co/K5TiwFA0L2 https://t.co/XoFsTMnxPC
Dr. John Cush @RheumNow( View Tweet )

EULAR 2026: Industry Press Releases

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic

Read Article
Curcumin in arthritis may have NSAID like clinical efficacy. But how? Metanalysis lays out the multiple potential effects for it to inhibit inflammatory signaling pathways (NF-κB, TNF-α, IL-1β, IL-6, COX-2, and PGE2) https://t.co/gSYVwpl41P https://t.co/0xZdyiF4QN
Dr. John Cush @RheumNow( View Tweet )

Guselkumab gets FDA Nod for X-ray Protection

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/eeyhso0WJ6 https://t.co/ZGWOOtf92E
Dr. John Cush @RheumNow( View Tweet )
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh
Dr. John Cush @RheumNow( View Tweet )
In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH
Dr. John Cush @RheumNow( View Tweet )

Count Your Telangiectasias (5.29.2026)

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush @RheumNow( View Tweet )

Increased Polypharmacy in SLE Patients

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

A

Read Article
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/tyd1efUtca https://t.co/zcY7RyX8SZ
Dr. John Cush @RheumNow( View Tweet )

Integrating D2T into T2T Practices in RA

EurekAlert!

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

Read Article

LRA Awards for Immune Resetting Therapies in Lupus

Lupus Research Alliance

Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of

Read Article
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush @RheumNow( View Tweet )

RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush @RheumNow( View Tweet )

The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as

Dr. John Cush @RheumNow( View Tweet )

Best JAKi? Italian Observational BIRRA Cohort study of 170 #PsA pts Rx w/ UPA or TOFA found no significance in 6 mos (86 vs 78%) or 12 mos (68 v 60%) retention. Persistence lower in pts Concomitant or later csDMARDs. https://t.co/vtSrO9orh4

Dr. John Cush @RheumNow( View Tweet )

RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's

A small, pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.

Read Article
×